Table 3 The relationship between clinicopathological features and the FIGO stage

Age, mean ± SD, y

60.16 ± 10.99

61.98 ± 10.27

0.297

Menopause, No. (%)

 No

22 (23.9%)

8 (12.5%)

0.075

 Yes

70 (76.1%)

56 (87.5%)

CA125, mean ± SD, U/ml

38.98 ± 75.74

89.96 ± 146.08

 < 0.001

 Normal

68 (81.0%)

30 (50.0%)

 < 0.001

 Elevated

16 (19.0%)

30 (50.0%)

Histology, No. (%)

 Mixed

29 (31.5%)

35 (54.7%)

0.004

 Pure

63 (68.5%)

29 (45.3%)

LVSI, No. (%)

 (-)

83 (90.2%)

34 (53.1%)

 < 0.001

 ( +)

9 (9.8%)

30 (46.9%)

MI, No. (%)

  < 1/2

71 (77.2%)

21 (33.3%)

 < 0.001

  ≥ 1/2

21 (22.8%)

42 (66.7%)

PWC, No. (%)

 (-)

79 (95.2%)

35 (68.6%)

 < 0.001

 ( +)

4 (4.8%)

16 (31.4%)

No. of postoperative chemotherapy cycles, mean ± SD

3.94 ± 2.02

4.71 ± 1.93

0.039

Recurrence, No. (%)

 No

81 (88.0%)

36 (56.3%)

 < 0.001

 Yes

11 (12.0%)

28 (43.7%)

Mean time to recurrence, mean ± SD, months

30.24 ± 30.33

11.57 ± 9.12

0.001

Death, No. (%)

 No

80 (87%)

44 (68.8%)

0.006

 Yes

12 (13%)

20 (31.2%)

Mean time to death, mean ± SD, months

64.00 ± 68.84

26.50 ± 21.07

0.024